Bell Potter retains a "speculative buy" on Starpharma with a price target at $1.15 a share.
"We are impressed with the speedy progress of the collaboration which is indicative both of [AZN] AstraZeneca's deep interest in SPL's DEP technology and also of its satisfaction with the results seen with the first DEP enhanced compound.
Loading...
Elise Shaw writes on Markets specialising in Equity Markets, Commodities, Mining. Based in our Sydney newsroom, Elise has over 25 years experience as a finance and markets journalist and editor. Connect with Elise on Twitter.
